H. Lundbeck 미래 성장

Future 기준 확인 1/6

H. Lundbeck (는) 각각 연간 8.6% 및 3.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 8.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 10.5% 로 예상됩니다.

주요 정보

8.6%

수익 성장률

8.8%

EPS 성장률

Pharmaceuticals 수익 성장	15.7%
매출 성장률	3.7%
향후 자기자본 수익률	10.5%
애널리스트 커버리지	Good
마지막 업데이트	15 Nov 2024

최근 미래 성장 업데이트

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

Recent updates

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

수익 및 매출 성장 예측

CPSE:HLUN B - 애널리스트의 미래 추정치 및 과거 재무 데이터 (DKK Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	24,638	4,074	5,156	5,624	9
12/31/2025	23,339	3,581	4,774	5,183	10
12/31/2024	22,053	3,039	4,316	4,689	9
9/30/2024	21,441	2,687	4,936	5,421	N/A
6/30/2024	20,671	2,586	4,128	4,609	N/A
3/31/2024	20,239	2,298	4,245	4,791	N/A
12/31/2023	19,912	2,290	3,579	4,080	N/A
9/30/2023	19,614	2,467	3,528	4,426	N/A
6/30/2023	19,381	2,479	3,523	4,457	N/A
3/31/2023	18,918	2,384	3,292	4,102	N/A
12/31/2022	18,246	1,916	2,699	3,519	N/A
9/30/2022	17,619	1,603	2,051	2,615	N/A
6/30/2022	16,913	1,236	1,744	2,313	N/A
3/31/2022	16,398	1,109	1,344	1,959	N/A
12/31/2021	16,299	1,318	1,660	2,272	N/A
9/30/2021	16,521	1,873	2,405	2,949	N/A
6/30/2021	16,971	1,965	2,379	2,912	N/A
3/31/2021	17,381	2,110	3,263	3,757	N/A
12/31/2020	17,672	1,581	3,359	3,837	N/A
9/30/2020	17,818	904	2,713	3,171	N/A
6/30/2020	17,490	1,242	2,910	3,354	N/A
3/31/2020	17,366	1,507	1,502	1,960	N/A
12/31/2019	17,036	2,313	2,165	2,609	N/A
9/30/2019	16,811	3,091	3,210	3,621	N/A
6/30/2019	17,309	3,395	2,736	3,462	N/A
3/31/2019	17,766	3,606	4,100	4,815	N/A
12/31/2018	18,117	3,907	5,277	5,981	N/A
9/30/2018	18,313	3,806	5,057	5,922	N/A
6/30/2018	18,028	3,627	N/A	6,197	N/A
3/31/2018	17,608	3,236	N/A	5,397	N/A
12/31/2017	17,234	2,624	N/A	4,045	N/A
9/30/2017	17,007	2,544	N/A	3,731	N/A
6/30/2017	16,607	1,988	N/A	3,551	N/A
3/31/2017	16,075	1,612	N/A	3,420	N/A
12/31/2016	15,634	1,211	N/A	3,126	N/A
9/30/2016	15,202	290	N/A	4,158	N/A
6/30/2016	14,923	-1,289	N/A	2,755	N/A
3/31/2016	14,801	-5,427	N/A	936	N/A
12/31/2015	14,594	-5,694	N/A	197	N/A
9/30/2015	14,108	-5,879	N/A	-1,330	N/A
6/30/2015	13,625	-4,615	N/A	-464	N/A
3/31/2015	13,444	-565	N/A	1,379	N/A
12/31/2014	13,468	-153	N/A	1,610	N/A
9/30/2014	13,808	503	N/A	2,601	N/A
6/30/2014	14,181	765	N/A	2,095	N/A
3/31/2014	14,269	119	N/A	2,982	N/A
12/31/2013	15,258	855	N/A	3,760	N/A

애널리스트 미래 성장 예측

수입 대 저축률: HLUN B 의 연간 예상 수익 증가율( 8.6% )이 saving rate( 1.2% 보다 높습니다. ).

수익 vs 시장: HLUN B 의 연간 수익( 8.6% ) Danish 시장( 11.6% 보다 느리게 성장할 것으로 예상됩니다. 11.6% 연간).

고성장 수익: HLUN B 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: HLUN B 의 수익(연간 3.7% ) Danish 시장( 10% 보다 느리게 성장할 것으로 예상됩니다. 10% 연간).

고성장 수익: HLUN B 의 수익(연간 3.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: HLUN B 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 10.5 %).

H. Lundbeck 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

Price target increased by 9.4% to kr.45.54

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

Investors Aren't Entirely Convinced By H. Lundbeck A/S' (CPH:HLUN B) Earnings

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Price target increased by 9.4% to kr.45.54

Do H. Lundbeck's (CPH:HLUN B) Earnings Warrant Your Attention?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Interested In H. Lundbeck A/S' (CPH:HLUN B) Earnings

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견